Triple-negative breast cancer: new hope
Giampaolo Bianchini
Biography
Dr. Giampaolo Bianchini is the leading specialist in breast oncology in the Department of Clinical Oncology at the Ospedale San Raffaele.
In 2000, Dr. Bianchini graduated from the Faculty of Medicine and Surgery at the University of Milan-Bicocca, and later he completed his specialization in Clinical Oncology at the University of Milan in 2004. In the beginning of his career as a visiting research fellow, he took part in various prestigious American institutions such as the National Cancer Institute (Bethesda), MD Anderson Cancer Center (Houston) and Yale Cancer Center (New Haven).
With 20 years of experience, Dr. Bianchini specializes in treating patients with early and metastatic breast carcinoma.
Movreover, he leads a team for Immunotherapy and Translational Clinical Research at the Department of Clinical Oncology and is actively involved in numerous research projects for women with breast carcinoma conducted for understanding the response mechanisms and resistance to existing drugs, identifying new therapeutic strategies, and biomarkers which helps to choose an individual treatment.
Dr. Bianchini also participates in studies aimed at identifying the mechanisms of response and resistance to immunotherapeutic drugs, as well as in the development of clinical trials for their use in the treatment of breast carcinoma and many other solid tumors.
Dr. Bianchini has an H-index equal to 22 thanks to numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology, which makes him a recognized expert in their field.
Education
University of Milan Bicocca
Degree in Medicine and Surgery
-
2000
University of Milan Bicocca
Medical Oncology Specialization
-
2004
Multimedia gallery
Publications
Dr. Bianchini is the author of numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology. Its H index is 22. He regularly participates in national and international congresses and symposia.